Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
Information source: OVO R & D
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Women With Fertility Disorder
Intervention: Glucagon (Drug); placebo (Drug)
Phase: Phase 4
Status: Withdrawn
Sponsored by: OVO R & D Official(s) and/or principal investigator(s):
Eric Himaya, Dr, Principal Investigator, Affiliation: clinique ovo and CHUM
Summary
The success of in vitro fertilization is based mainly on uterine implantation embryo. An
excessive uterine contractility may interfere with implantation by a movement of the embryo
in the uterus. The inhibition of the uterine contractility may have a positive effect on
success rate of in vitro fertilization. It is through parenteral injection of glucagon and
its spasmolytic effect on various smooth muscles and thereby on the uterine muscle, at the
time of embryo transfer, the investigators intend to improve the pregnancy rates obtained
after IVF.
Clinical Details
Official title: Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Uterine muscle relaxation
Secondary outcome: Embryo implantation and pregnancy rate
Detailed description:
Women will have a cycle of in vitro fertilization (IVF) and follow the standard protocol
established by the clinic ovo or the fertility clinic of CHUM. On the day of embryo
transfer, the investigators will administer 1 mg of Glucagon or placebo intramuscularly 10
minutes before the embryo transfer. The uterine contractility will be measured by ultrasound
before and after injection to document the impact of Glucagon on it and we will proceed to
embryo transfer.
Eligibility
Minimum age: 18 Years.
Maximum age: 40 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Women doing fertility treatment at the clinic ovo or fertility clinic of CHUM
- Less than 40 years old
- Women with stimulate in vitro fertilization cycle
- Women able to give her consent
Exclusion Criteria:
- Body mass index > 35 kg/m2
- Women with diabetes
- Women with hypertensive disorders
- Women with a blood pressure greater or equal to 140/90 mmHg at the randomization
visit
- Cons-indication to taking Glucagon:
- Hypersensitivity to product
- Pheochromocytoma or history of pheochromocytoma
- Insulinoma
- Taking a beta-blocker (drug interactions)
Locations and Contacts
Clinique Ovo, Montréal, Quebec H4P 2S4, Canada
Additional Information
Starting date: October 2013
Last updated: July 24, 2015
|
